Cancer is emerging as a leading cause of death globally. Considering the disease burden, scientists are working to develop various strategies by exploring natural sources for cancer treatment. The use of olive oil (OO) and its phytochemicals, specifically oleuropein and hydroxytyrosol (HT), as a remedy against various types of cancer is gaining attention among scientists and researchers. The current review aimed to highlight the antioxidant potential and summarize the various pathways and markers involved in the prevention and treatment of different human cancers. The databases, including Google Scholar, PubMed, and Web of Science, were searched to collect relevant data. The studies showed that some markers are specifically linked to particular types of cancers (such as 27-OHC, ATF-2, TNFRSF10B, HER2, and MET, which are linked to breast cancer; iNOS and NO, which are linked to thyroid cancer; GLUT1 and GLUT4, HIF-1α, MCT4, PKM2, PD-1, PD-L1, and CTLA-4, which are linked to colorectal cancer). Olive oil is involved in the management of these markers to prevent and/or treat all types of cancers by upregulating tumor suppressor genes, downregulating oncogenes, and modulating different pathways (PI3K/AKT/mTOR, Wnt/β-catenin, and MAPK). Taken together, it can be concluded that olive oil and its components have prominent potential to cure cancers in the human body. However, further investigations can be carried out to suggest the lethal doses of olive oils as a whole and its phytochemicals individually for the treatment of cancer.
Nanotechnology-enhanced materials and smart implants are emerging technologies that have shown promise in addressing various challenges in general surgery, including infection management, oncologic staging, and complication monitoring. In this systematic review, we aimed to examine the safety and efficacy of these technologies compared with conventional methods in patients undergoing general surgical procedures. A comprehensive search was conducted in MEDLINE (via PubMed), Embase, Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, WHO ICTRP, IEEE Xplore/Inspec, and Google Scholar according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, using standardized keywords related to nanotechnology, surgery, and clinical outcomes. The included studies were categorized according to intervention class and procedural type. Risk of bias was assessed using RoB 2 for randomized trials and ROBINS-I for nonrandomized studies, while outcome certainty was evaluated using GRADE. Nine eligible studies were included, comprising a total of 2,250 participants (infection prevention: 974; mapping/staging: 1,244; sensing: 32 drain-fluid samples). Due to heterogeneity among the studies, a meta-analysis could not be performed, and the results were therefore synthesized narratively. Silver-based topical creams and dressings demonstrated early bacterial clearance and improved wound healing. Carbon nanoparticle (CNP) suspensions enhanced lymph node detection sensitivity and preserved parathyroid hormone in thyroid cancer and nearly doubled sensitivity to micrometastatic lymph nodes in gastric cancer. Silver-ion-impregnated tracers in breast cancer showed comparable sensitivity for sentinel lymph node detection. Silver-ion-impregnated meshes showed no significant difference compared with conventional meshes. Overall, adverse effects were minimal or absent. In conclusion, nanotechnology-enhanced materials and smart implants show substantial potential to improve infection prevention, oncologic staging, and perioperative monitoring in general surgery, with minimal adverse effects. Silver-based topical antimicrobials, CNP suspensions, superparamagnetic iron oxide tracers, and innovative biosensor technologies were either comparable or superior to conventional alternatives. However, a clear knowledge gap regarding long-term outcomes and the heterogeneity of comparators highlights the need for larger, rigorously designed studies to guide clinical adoption.
smart implantsgeneral surgerysurgical site infection preventionlymphatic mapping
Background: Differentiated thyroid cancer (DTC) is the most prevalent endocrine malignancy with a recurrence rate of about 20%, necessitating better predictive methods for patient management. This study aims to create a relational classification model to predict DTC recurrence by integrating clinical, pathological, and follow-up data. Methods: The balanced dataset comprises 550 DTC samples collected over 15 years, featuring 13 clinicopathological variables. To address the class imbalance in recurrence status, the Synthetic Minority Over-sampling Technique for Nominal and Continuous (SMOTE-NC) was utilized. A hybrid model combining classification algorithms with association rule mining was developed. Two relational classification approaches, regularized class association rules (RCAR) and classification based on association rules (CBAR), were implemented. Binomial logistic regression analyzed independent predictors of recurrence. Model performance was assessed through accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and F1 score. Results: The RCAR model demonstrated superior performance over the CBAR model, achieving accuracy, sensitivity, and F1 score of 96.7%, 93.1%, and 96.7%, respectively. Association rules highlighted that papillary pathology with an incomplete response strongly predicted recurrence. The combination of incomplete response and lymphadenopathy was also a significant predictor. Conversely, the absence of adenopathy and complete response to treatment were linked to freedom from recurrence. Incomplete structural response was identified as a critical predictor of recurrence risk, even with other low-recurrence conditions. Conclusion: This study introduces a robust and interpretable predictive model that enhances personalized medicine in thyroid cancer care. The model effectively identifies high-risk individuals, allowing for tailored follow-up strategies that could improve patient outcomes and optimize resource allocation in DTC management.
Background: Thyroid cancer (TC) is becoming more prevalent in Saudi Arabia, currently ranking among the top three cancers affecting women. Despite its rising prevalence, there has been limited assessment of the factors influencing the survival rate (SR) among the Saudi population over an extended period. Therefore, this study aims to address this critical gap in knowledge by identifying the factors affecting the SR of TC, comparing the SR with previous studies, and exploring potential areas for improving the SR of patients. Methods: A retrospective study analyzed secondary data from patients diagnosed with TC, as recorded in the King Abdulaziz Medical City Cancer Registry in Riyadh, Saudi Arabia, over 10 years from 2009 to 2018. Results: Of the total 665 TC cases, the mean age at diagnosis was 46.2 years (±SD 16), and most patients were women (78.5%), with the majority being under 50 years old. The most common type of cancer was papillary thyroid carcinoma, comprising 88.6% of all TCs. Over half of the cases were localized to one of the lobes of the thyroid gland, with almost equal frequency between the two lobes. The 5-year SR of localized papillary thyroid carcinoma reached 96.5%, in contrast to the extremely low SR of anaplastic thyroid carcinoma, where most patients died within a few months of the diagnosis. Factors such as morphology, tumor extension, male gender, and age at diagnosis significantly impacted patient survival, as analyzed by the Kaplan–Meier test ( p < 0.001). Compared to other types of cancer, those with anaplastic thyroid carcinoma had a lower SR. Conclusion: The SR of TC patients is predicted by factors such as their age, morphological type, and the presence of distant metastasis.
Journal of Epidemiology and Global Health · مجلد 10 (4) · 258-258
BACKGROUND: Cancer epidemiology in Saudi Arabia (SA) differs from that of the USA with respect to types of common malignancies. Hematologic malignancies are among the top five cancers prevalent in SA, including lymphoma and leukemia. Most common malignancies in SA also include breast, thyroid, and colorectal cancer. We sought to evaluate the current trends of these most common cancers in SA. METHODS: Electronic search analysis pertaining to Hodgkin's lymphoma, leukemia, breast, colorectal, and thyroid cancer were carried out from two databases: The Saudi Cancer Registry (SCR) and the Surveillance, Epidemiology, and End Results (SEER). Data on prevalence and incident frequency were collected. Trends from 2001 to 2014 were calculated and compared between SCR and SEER. FINDINGS: Leukemia is the most common cancer type among males in SA, followed by colorectal cancer. Hodgkin's lymphoma has become the third most common malignancy among Saudi males. Percentage of women's breast cancer and thyroid cancer among total cancer cases have increased by 10.5% and 1.7% respectively from 2001 to 2014, making them the first and second most common cancers in women respectively. Trends of thyroid cancer among males has been stable. Colorectal cancer stands as third most common among Saudi females. INTERPRETATIONS: There have been significant changes in trends of incidence rate of the most common cancers in SA among both males and females over the past decade. Breast cancer rates have risen at an alarming pace. More epidemiological studies need to be conducted to evaluate etiological factors at environmental, molecular, and genetic levels.
cancer incidence trendsSaudi Arabiabreast cancerthyroid cancer